Is the Worst Over for UnitedHealth Group Stock?

UnitedHealth Group (UNH) has shown signs of stabilization and a recent rally, despite earlier underperformance and missed analyst expectations. The company reaffirmed its 2025 adjusted EPS guidance of at least $16 and projected an encouraging 2026 outlook with 78% of members in highly-rated Medicare plans. This positive sentiment was bolstered by Berkshire Hathaway's mid-August purchase of 5 million shares, which catalyzed a stock surge from approximately $270 to over $336. Despite remaining down over 40% in the last 12 months, UNH trades at roughly 15x trailing earnings with a 2.6% dividend yield, suggesting potential limited downside and an attractive valuation.

Analysis

UnitedHealth Group (UNH) is showing signs of stabilization following a significant period of underperformance that drove its stock down over 40% in the past 12 months. The recent recovery has been catalyzed by two primary factors: a significant institutional endorsement and stabilizing forward guidance. In mid-August, Berkshire Hathaway's purchase of 5 million shares signaled a strong value proposition, triggering a rally that lifted the stock from approximately $270 to over $336. Operationally, UNH reaffirmed its 2025 adjusted earnings per share (EPS) forecast of at least $16. While this figure is substantially below prior Wall Street estimates of nearly $21, its confirmation suggests a potential floor for earnings and that conditions are no longer deteriorating. Further bolstering long-term confidence is a preliminary 2026 outlook projecting that 78% of its members will be in highly-rated Medicare plans, which secures larger government payments. Despite the recent rally, the stock trades at an attractive valuation of approximately 15 times trailing earnings, supported by $21.3 billion in profit over the last twelve months and offering a 2.6% dividend yield, which is more than double the S&P 500 average.

Key Decisions for Investors

• Given the stock's significant decline over the past year and its current valuation at approximately 15 times trailing earnings, Berkshire Hathaway's recent 5 million share purchase serves as a strong value signal, potentially marking an attractive entry point.
• Investors should closely monitor upcoming quarterly reports to confirm the company remains on track to meet its reaffirmed 2025 adjusted EPS guidance of at least $16, as this is a key pillar supporting the current stabilization thesis.
• The combination of a 2.6% dividend yield and a positive 2026 outlook for its high-margin Medicare business may appeal to income-focused and long-horizon investors who can look past recent volatility.